The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year

Melda Turken; Gulsun Cavdar; Gulgun Akkoclu; Sukran Kose

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year

Author(s):

Melda Turken,

Gulsun Cavdar,

Gulgun Akkoclu,

Sukran Kose^1,*

1Tepecik Research and Training Hospital, Clinic of Clinical Microbiology and Infectious Diseases, Tepecik, Izmir, Turkey

Hepatitis Monthly:Vol. 10, issue 4; 289-293

Published online:Dec 31, 2010

Article type:Research Article

Received:Feb 02, 2010

Accepted:Aug 20, 2010

How to Cite:Turken M, Cavdar G, Akkoclu G, Kose S. The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year.Hepat Mon.2010;10(4):289-293.

Abstract

Background and Aims: We aimed to evaluate the effectiveness of nucleoside analogues such as Lamivudine, Adefovir, Entacavir, and Tenofovir in patients with chronic hepatitis B who failed to respond to interferon therapy and relapsed.
Materials and Methods: We followed a total of 73 patients with hepatitis B in the hepatitis outpatient clinic in our hospital. The patients subsequently received nucleoside analogues therapy and their treatment data were evaluated retrospectively. The biochemical and virological response rates were evaluated at 3 and 12 months, and we compared these results with the results of treatment-naive patients.
Results: There were 29 (39.7%) HbeAg-positive and 44 (60.3%) HbeAg-negative patients, and their mean age was 35.8 (±13.4) years. Of these patients, 33, 18, 13 and 9 received Entacavir, Tenofovir, Lamivudine, and Adefovir treatment, respectively. In HbeAg-negative patients, at 3 months the biochemical and virological response (early response) rates were observed to be 91% and 98%), and at 12 months the two rates were 93% and 73%, respectively. In HbeAg-positive patients, the biochemical and virological response rates at 3 months were 83% and 97%, and the rates at 12 months were 90% and 48%, respectively.
Conclusions: In CHB therapy with treatment-resistent patients, nucleoside analogues may be preferable. There are disadvantages to nucleoside analogues, such as a risk of developing resistance during therapy, reduced HBeAg seroconversion compared to interferons, and the therapy's ambiguous duration. In our study, in HbeAg-negative patients who received nucleoside analogues, a lower biochemical response rate was detected in patients with 1 year of Lamivudine therapy compared to other therapies. For HbeAg-positive patients, the virological response rate was higher in 1 year of Tenofovir therapy than with other therapies.

Keywords

Hepatitis B Virus

nucleoside analogues

interferon therapy

Fulltext

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 1 month ago
Scopus by Title: 5
Last Update: 1 month ago
Scopus by Title (Ref): 5
Last Update: 1 month ago
CrossRef: 0
Last Update: 2 days ago

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Melda Turken:[PubMed][Scholar]
Gulsun Cavdar:[PubMed][Scholar]
Gulgun Akkoclu:[PubMed][Scholar]
Sukran Kose:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year

Abstract

Fulltext

Last Update: 1 month ago

Last Update: 1 month ago

Last Update: 1 month ago

Last Update: 2 days ago